KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Operating Expenses: 2009-2025

Historic Operating Expenses for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to $822.8 million.

  • Biomarin Pharmaceutical's Operating Expenses rose 30.23% to $822.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 3.15%. This contributed to the annual value of $2.4 billion for FY2024, which is 6.10% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Operating Expenses stood at $822.8 million for Q3 2025, which was up 50.01% from $548.5 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Operating Expenses high stood at $822.8 million for Q3 2025, and its period low was $382.0 million during Q1 2022.
  • For the 3-year period, Biomarin Pharmaceutical's Operating Expenses averaged around $590.5 million, with its median value being $560.4 million (2024).
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Operating Expenses declined by 17.12% in 2022, and later skyrocketed by 39.78% in 2023.
  • Biomarin Pharmaceutical's Operating Expenses (Quarterly) stood at $515.7 million in 2021, then rose by 6.77% to $550.6 million in 2022, then grew by 12.40% to $618.9 million in 2023, then dropped by 5.34% to $585.9 million in 2024, then skyrocketed by 30.23% to $822.8 million in 2025.
  • Its Operating Expenses was $822.8 million in Q3 2025, compared to $548.5 million in Q2 2025 and $521.3 million in Q1 2025.